Rheumatologists know HCQ as the single most useful agent for lupus, and ophthalmologists know HCQ as a preventable cause of retinopathy that can result in blindness. Ophthalmologists, not rheumatologists, published the latest guidelines.
During Monday’s Paul Klemperer, MD Memorial Lecture, Josef S. Smolen, MD, discussed the pathways to joint destruction in RA and reviewed evidence supporting the relationship between clinical disease activity and progression of articular damage.
More research is needed using multisite, different research designs, and involvement of people with scleroderma to determine evidence-based non-pharmaceutical interventions for scleroderma, according to this year’s ARHP Distinguished Lecturer.
Rachel L. Glaser, MD, Clinical Team Leader, Division of Pulmonary, Allergy, and Rheumatology Products for the FDA, reviewed the results from the PRECISION trial and other studies impacting rheumatology.
The Accelerating Medicines Partnership (AMP) is beginning to see early data from its network of investigators working in rheumatology. Some of that early data will be shared at an ACR Basic Science track session on Tuesday.